PRODUCT

EB8018 + IBD210

The current therapeutic algorithm for CD does not take into account the site of inflammation or composition of intestinal microbiome. Moreover, dysregulated intestinal immunity and overproduction of proinflammatory cytokines are not the only components of CD pathophysiology. Intestinal microbiome is abnormal and plays an important role in the pathogenesis of CD.

An E. coli species with adhesive and invasive properties, adherent-invasive E. coli (AIEC), has been described in ileal mucosa of patients with CD. AIEC has been found in >50% of patients with ileal CD and 6% of controls. The role of AIEC in CD has been thoroughly investigated in several laboratories around the world and has shown that AIEC is proinflammatory and could play an important role in intestinal inflammation associated with CD.

There is a strong possibility that as in a number of conditions not previously believed to have a microbial cause, the chronic inflammation seen in the gut wall of IBD patients could be associated with a bacterial infection by AIEC. Until recently stomach ulcer was believed to be a disease induced by an altered regulation of acid secretion in the stomach. H. pylori was first discovered in the stomachs of patients with gastritis and stomach ulcers in 1982.

Enterome small molecule drug EB8018 is a first in class FimH antagonist inhibiting AIEC adhesion in the ileum of CD patients. It will be first used as an add-on therapy on standard of care treatments for moderate-to-severe CD. The eligible population will roughly be the same than the whole moderate-to-severe patient population.

The aim of Enterome is also to develop a non-invasive screening test (IBD210) for AIEC detection which will also constitute a companion test for the treatment.

EB8018 + IBD210EB110 + EB120IBD110